Overview:

IDO1 encodes indoleamine 2,3-dioxygenase (IDO) - a heme enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine which acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. IDO1 play a main role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity. IDO1 activity in tumor cells may act to impair antitumor responses (1). The efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor (2).

Gene Aliases:

CD107B, IDO, INDO

Genbank Number:

BC027882

References:

1. Logan, G. J. et.al: HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity. Immunology 105: 478-487, 2002.

2. Uyttenhove, C.et.al: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Med. 9: 1269-1274, 2003.